Primary Prophylaxis for Cryptococcosis With Fluconazole in Human Immunodeficiency Virus-Infected Patients With CD4 T-Cell Counts <100 Cells/µL and Receiving Antiretroviral Therapy.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 28362939.
- Also identified by DOI 10.1093/cid/cix036.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A prospective observational cohort study was conducted in 302 human immunodeficiency virus-infected patients who had a CD4 T-cell count <100 cells/µL and negative serum cryptococcal antigen initiating antiretroviral therapy in a resource-limited setting. During 2-year follow-up, there were no differences of survival rates and occurrences of newly diagnosed cryptococcosis between patients with and without fluconazole for primary prophylaxis of cryptococcosis.
Medical subject headings
- AIDS-Related Opportunistic Infections
- Antifungal Agents
- CD4 Lymphocyte Count
- Cryptococcosis
- Fluconazole
- HIV Infections